PacRim7 7th PacRim Meeting Poster Presentations (1) (52 abstracts)
Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer
L Castillo 1 , S George 1 , H-M Lin 1 , N Yeung 1 , A Mawson 1 , AI Young 1 , AM Law 1 , J Hastings 1 , D Gallego-Ortega 1, , N Deng 1 , D Croucher 1, , A Swarbrick 1, , L Horvath 3, , CJ Ormandy 1, & SR Oakes 1,
1The Kinghorn Cancer Centre, Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia; 2St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, NSW, 2010, Australia; 3Chris O’Brien Lifehouse, Sydney, Australia; 4Garvan Institute of Medical Research, Sydney, Australia; 5University of NSW, Sydney, Australia; 6University of Sydney, Sydney, Australia.
The ability to survive is essential for carcinogenesis. We previously showed that in to addition promoting cancer cell survival, Myeloid Cell Leukemia 1 (MCL-1) regulates cancer cell invasion possibly via direct regulation of the cytoskeletal protein Cofilin and via modulation of the output of the SRC family kinase pathway. We also showed that dual inhibition of MCL-1 and SRC family kinases was effective in suppressing metastasis of breast cancer intraductal xenografts made from immortalized triple negative breast cancer cells. We are now exploring the potential of targeting MCL-1 alone or in combination with dasatinib and taxane-based cytotoxic therapy in clinically relevant models of metastatic breast and prostate cancer. Here we will report the findings from this study and the progress of a systems biology approach to predicting response.
Article tools
My recent searches
My recently viewed abstracts
Authors
Oncology Abstracts
ISSN 2631-4657 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more